Trial · NCT05122650
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 12 on the TETRAS Composite Outcome Score as Summarized by Each Dose of JZP385 and Placebo | Placebo | -6.3 | Standard Deviation 6.22 | score on a scale | |
| Change From Baseline to Week 12 on the TETRAS Composite Outcome Score as Summarized by Each Dose of JZP385 and Placebo | 10 Milligram (mg) JZP385 | -5.8 | Standard Deviation 6.85 | score on a scale | |
| Change From Baseline to Week 12 on the TETRAS Composite Outcome Score as Summarized by Each Dose of JZP385 and Placebo | 20 mg JZP385 | -6.7 | Standard Deviation 6.88 | score on a scale | |
| Change From Baseline to Week 12 on the TETRAS Composite Outcome Score as Summarized by Each Dose of JZP385 and Placebo | 30 mg JZP385 | -7.5 | Standard Deviation 7.31 | score on a scale | |
| Percentage of Participants Who Improved (≥ 1-Point Improvement) From Baseline to Week 12 on the Clinical Global Impression- Severity Scale (CGI-S) | Placebo | 50.0 | Percentage of participants | ||
| Percentage of Participants Who Improved (≥ 1-Point Improvement) From Baseline to Week 12 on the Clinical Global Impression- Severity Scale (CGI-S) | 10 Milligram (mg) JZP385 | 49.8 | Percentage of participants | ||
| Percentage of Participants Who Improved (≥ 1-Point Improvement) From Baseline to Week 12 on the Clinical Global Impression- Severity Scale (CGI-S) | 20 mg JZP385 | 55.7 | Percentage of participants | ||
| Percentage of Participants Who Improved (≥ 1-Point Improvement) From Baseline to Week 12 on the Clinical Global Impression- Severity Scale (CGI-S) | 30 mg JZP385 | 62.8 | Percentage of participants | ||
| Proportion of Participants Reported as Much Improved on the Clinical Global Impression of Change (CGI-C) at Week 12 | Placebo | 22 | Participants | ||
| Proportion of Participants Reported as Much Improved on the Clinical Global Impression of Change (CGI-C) at Week 12 | 10 Milligram (mg) JZP385 | 18 | Participants | ||
| Proportion of Participants Reported as Much Improved on the Clinical Global Impression of Change (CGI-C) at Week 12 | 20 mg JZP385 | 19 | Participants | ||
| Proportion of Participants Reported as Much Improved on the Clinical Global Impression of Change (CGI-C) at Week 12 | 30 mg JZP385 | 30 | Participants | ||
| Proportion of Participants Reported as Much Improved on the Patient Global Impression of Change (PGI-C) at Week 12 | Placebo | 16 | Participants | ||
| Proportion of Participants Reported as Much Improved on the Patient Global Impression of Change (PGI-C) at Week 12 | 10 Milligram (mg) JZP385 | 11 | Participants | ||
| Proportion of Participants Reported as Much Improved on the Patient Global Impression of Change (PGI-C) at Week 12 | 20 mg JZP385 | 20 | Participants | ||
| Proportion of Participants Reported as Much Improved on the Patient Global Impression of Change (PGI-C) at Week 12 | 30 mg JZP385 | 32 | Participants | ||
| Change From Baseline to Week 12 on the TETRAS-ADL Subscale as Summarized by Each Dose of JZP385 and Placebo | Placebo | -6.4 | Standard Deviation 6.40 | score on a scale | |
| Change From Baseline to Week 12 on the TETRAS-ADL Subscale as Summarized by Each Dose of JZP385 and Placebo | 10 Milligram (mg) JZP385 | -6.3 | Standard Deviation 7.55 | score on a scale | |
| Change From Baseline to Week 12 on the TETRAS-ADL Subscale as Summarized by Each Dose of JZP385 and Placebo | 20 mg JZP385 | -7.1 | Standard Deviation 7.88 | score on a scale | |
| Change From Baseline to Week 12 on the TETRAS-ADL Subscale as Summarized by Each Dose of JZP385 and Placebo | 30 mg JZP385 | -8.7 | Standard Deviation 8.49 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05122650/results